Molecular alterations in Hürthle cell nodules and preoperative cancer risk

in Endocrine-Related Cancer
View More View Less
  • 1 W Doerfler, Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, United States
  • 2 A Nikitski, Department of Pathology, University of Pittsburgh, Pittsburgh, United States
  • 3 E Morariu, Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, United States
  • 4 N Ohori, Department of Pathology, University of Pittsburgh, Pittsburgh, PA 200 Lothrop Street, Pittsburgh, PA 15213, Pittsburgh, United States
  • 5 S Chiosea, Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, United States
  • 6 M Landau, Department of Pathology, University of Pittsburgh, Pittsburgh, United States
  • 7 M Nikiforova, Pathology, University of Pittsburgh, Pittsburgh, United States
  • 8 Y Nikiforov, Pathology and Laboratory Medicine, University of Pittsburgh, Pittsburgh, 15213, United States
  • 9 L Yip, Surgery, University of Pittsburgh, Pittsburgh, United States
  • 10 P Manroa, Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, United States

Correspondence: Pooja Manroa, Email: pomanroa@utmb.edu
Restricted access

Hürthle cell carcinoma (HCC) is a distinct type of thyroid cancer genetically characterized by DNA copy number alterations (CNA), typically of genome haploidization type (GH-type). However, whether CNA also occur in benign Hürthle cell adenomas (HCA) or Hürthle cell hyperplastic nodules (HCHN), and have diagnostic impact in fine needle aspiration (FNA) samples, remains unknown. To address these questions, we (i) analyzed 26 HCC, 24 HCA, and 8 HCHN tissues for CNA and other mutations using ThyroSeq v3 (TSv3) next-generation sequencing panel, and (ii) determined cancer rate in 111 FNA samples with CNA and known surgical outcome. We identified CNA, more often of the GH-type, in 81% of HCC and in 38% HCA, but not in HCHN. Among 4 HCC with distant metastasis, all had CNA and 3 TERT mutations. Overall, positive TSv3 results were obtained in 24 (92%) HCC, including all with ATA high risk of recurrence or metastasis. Among 111 FNA cases with CNA, 38 (34%) were malignant, and 73 (66%) benign. A significant correlation between cancer rate and nodule size was observed, particularly among cases with GH-type CNA, where every additional centimeter of nodule size increased the malignancy odds by 1.9 (95% CI 1.3-2.7; P=0.001). In summary, the results of this study demonstrate that CNA characteristic of HCC also occur in HCA, although with lower frequency, and probability of cancer in nodules with CNA increases with nodule size. Detection of CNA, in conjunction with other mutations and nodule size, is helpful in predicting malignancy in thyroid nodules.

 

Society for Endocrinology